Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

While sales of both drugs have been rising on a sequential and yearly basis, the reported figures missed the consensus estimate of $4.3 billion for Mounjaro and $2.2 billion for Zepbound.

Lilly’s total revenues for the fourth quarter fell short of expectations due to lower-than-expected sales of its popular GLP-1 drugs, Mounjaro for type II diabetes and Zepbound for obesity.

She advises against touching, rubbing, or massaging the treated area for about 24 hours and to avoid working for about 48 hours post-injection. While most will start to notice the appearance of ...

Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the second consecutive miss for the two closely watched ...

(Reuters) -Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed ...

Lilly expects its most-watched blockbuster products — GLP-1 tirzepatide products Mounjaro and Zepbound — to miss consensus as well. Guidance for diabetes drug Mounjaro is $3.5 billion ...

That would be bad news for Lilly, which makes competing GLP-1 drugs Zepbound and Mounjaro. For now, Medicare does not cover drugs prescribed specifically for weight loss, but it will cover GLP-1 ...

Of note, however, at peak times, the oral DehydraTECH-tirzepatide-induced insulin levels were as much as approximately 100% higher than those from the Zepbound® injection. "Lexaria is delighted ...